MAST CELL STABILIZATION AND BRONCHOSPASM INHIBITION BY ARITHRATHI CHOORANAM, A TRADITIONAL SIDDHA MEDICINE: EVIDENCE FROM PRECLINICAL STUDIES
Main Article Content
Abstract
Background: Allergic disorders, including asthma, pose a significant health burden worldwide, with increasing prevalence due to environmental and genetic factors. Conventional treatments often have limitations in efficacy and safety, necessitating the exploration of alternative therapies. The Siddha system of medicine offers promising herbal formulations, such as Arithrathi Chooranam, traditionally used for respiratory ailments. This study evaluates its antihistaminic and antianaphylactic potential.
Methods: The study assessed mast cell stabilizing and bronchospasm inhibitory effects of Arithrathi Chooranam in animal models. Wistar rats were sensitized using horse serum and Bordetella pertussis antigen, followed by treatment with the formulation (200 mg/kg and 400 mg/kg orally). The percentage of degranulated mast cells was measured. In guinea pigs, histamine-induced bronchospasm was evaluated by determining the preconvulsive dyspnea (PCD) latency after exposure to histamine aerosol. Statistical analyses were conducted using one-way ANOVA.
Results: Arithrathi Chooranam demonstrated significant mast cell stabilization, reducing degranulated mast cells (P < 0.001). In histamine-induced bronchospasm, treatment prolonged PCD latency (P < 0.001), indicating an antihistaminic effect. These findings suggest its potential role in modulating allergic responses and preventing airway hyperresponsiveness.
Conclusion: Arithrathi Chooranam exhibits significant antianaphylactic and antihistaminic properties, supporting its traditional use for allergic and respiratory disorders. Further research is warranted to elucidate its molecular mechanisms and clinical applicability.
Methods: The study assessed mast cell stabilizing and bronchospasm inhibitory effects of Arithrathi Chooranam in animal models. Wistar rats were sensitized using horse serum and Bordetella pertussis antigen, followed by treatment with the formulation (200 mg/kg and 400 mg/kg orally). The percentage of degranulated mast cells was measured. In guinea pigs, histamine-induced bronchospasm was evaluated by determining the preconvulsive dyspnea (PCD) latency after exposure to histamine aerosol. Statistical analyses were conducted using one-way ANOVA.
Results: Arithrathi Chooranam demonstrated significant mast cell stabilization, reducing degranulated mast cells (P < 0.001). In histamine-induced bronchospasm, treatment prolonged PCD latency (P < 0.001), indicating an antihistaminic effect. These findings suggest its potential role in modulating allergic responses and preventing airway hyperresponsiveness.
Conclusion: Arithrathi Chooranam exhibits significant antianaphylactic and antihistaminic properties, supporting its traditional use for allergic and respiratory disorders. Further research is warranted to elucidate its molecular mechanisms and clinical applicability.
Article Details
Issue
Section
Articles